Month: September 2024

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 6, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that sales of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer in Europe exceeded the threshold that triggered a milestone payment of USD 25 million to Basilea. David Veitch, Chief Executive Officer of Basilea, said: “We are very pleased with the continued recognition of Cresemba in meeting the critical medical needs of patients with life-threatening invasive mold infections, and its strong sales performance in Europe, which has resulted in this milestone payment. We already announced several sales milestone payments from sales in Asia...

VANCOUVER, British Columbia, Sept. 05, 2024 (GLOBE NEWSWIRE) — Bunker Hill Mining Corp. (“Bunker Hill” or the “Company”) (TSX-V: BNKR; OTCQB: BHLL) announces that it has elected to issue 506,775 shares of common stock (the “Shares”) at a deemed issue price of C$0.16 per Share to a certain creditor of the Company (the “Creditor”) in full satisfaction of the aggregate US$60,000 financing cooperation fee owing to the Creditor for the three (3) month period beginning on April 1, 2024 and ending on June 30, 2024 (the “Q2 Cooperation Fee”) pursuant to the terms of an agreement re financing cooperation dated September 27, 2022 (the “Cooperation Agreement”) entered into by and among the Company and the Creditor. The Cooperation Agreement provides for, among other things, the Creditor and its affiliates providing certain collateral security...

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) — Varonis Systems, Inc. (Nasdaq: VRNS) (“Company” or “Varonis”), announced today that it priced a private offering of $400 million aggregate principal amount of 1.00% Convertible Senior Notes due 2029 (the “Notes”). The Notes will only be sold to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $350 million aggregate principal amount of notes. The Company also granted to the initial purchasers of the Notes a 13-day option to purchase up to an additional $60 million aggregate principal amount of Notes. The sale is expected to close on September 10, 2024, subject to satisfaction of the conditions to closing. The...

Forekast connects today’s business needs to tomorrow’s technology. Forekast continues to innovate, offering flexible and scalable solutions tailored to meet the evolving needs of clients across multiple industries. NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) — Evergreen Corporation (NASDAQ: EVGR), a special purpose acquisition company (“EVGR”), today announced that they have entered into a definitive agreement and plan of merger (the “Business Combination Agreement”) under which EVGR will merge with Forekast Limited (“Forekast”). Following the closing, the combined company will operate as Forekast Group (“PubCo”). Forekast is a technology managed services provider specializing in augmented intelligence, integrating AI-driven insights to enhance business operations, customer experiences, and workforce capabilities. Forekast has a...

Highlights:An additional $5,000,000 has been raised in a second round of Special Warrant and Unit offerings, following on from first round offerings totaling $3,679,564 closed in July. More than $8.68 million has been raised between the two recent offerings. Alaska Energy Metals is now adequately funded for the drilling program planned and underway at the Nikolai nickel project in Alaska; drilling commenced in July and has been completed on the Canwell prospects. Drilling is underway to test for extensions of the Eureka nickel deposit. Metallurgical studies to determine metal recovery rates have been initiated.VANCOUVER, British Columbia, Sept. 05, 2024 (GLOBE NEWSWIRE) — Alaska Energy Metals Corporation (TSX-V: AEMC, OTCQB: AKEMF) (“AEMC” or the “Company”) is pleased to announce that it has closed its non-brokered offering...

Top-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial in patients with decreased visual acuity under low light conditions following keratorefractive surgery expected in first quarter of 2025 FARMINGTON HILLS, Mich., Sept. 05, 2024 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that the VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% for presbyopia has dosed its first participants. Presbyopia, the gradual loss of ability to focus on near objects, typically becomes noticeable in the early to mid-40s. This progressive and ubiquitous...

Fort Lauderdale, Florida, Sept. 05, 2024 (GLOBE NEWSWIRE) — Vine Hill Capital Investment Corp. (the “Company”), a special purpose acquisition company, today announced the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per unit. The units are expected to be listed for trading on the Nasdaq Global Market (“Nasdaq”) under the ticker symbol “VCICU” beginning September 6, 2024. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant of the Company. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. Once the securities comprising the units begin separate trading, the Company expects that its Class A ordinary shares and warrants will be listed on Nasdaq under the symbols ‘‘VCIC”...

Perth, Sept. 06, 2024 (GLOBE NEWSWIRE) —          Perseus Mining Limited (ASX/TSX:PRU) (Perseus or the Company) is pleased to announce that it has increased its relevant interest in the issued shares of Predictive Discovery Limited (ASX:PDI) (Predictive) to 19.9%. As part of funding the acquisition of this increased stake in Predictive, Perseus has applied the proceeds raised from the unwinding of its previously announced cash settled equity swap position in Predictive1. Further details of Perseus’s interests in Predictive will be set out in a Form 604 Notice of Change of Substantial Interest to be released on the ASX platform. Subject to there being no actual or proposed material change in the shareholding of Predictive (including a change of control proposal) or the actions of Predictive, Perseus has no current intention to acquire...

EDEN PRAIRIE, Minn., Sept. 05, 2024 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its upcoming virtual investor presentation at the H.C. Wainwright 26th Annual Global Investment Conference being held in-person and virtually on September 9-11, 2024. The Company’s virtual presentation by Chief Operating Officer Chris Volker will be available on demand beginning at 7:00 a.m. ET on Monday, September 9, 2024, through the end of the conference. To access the presentation, investors can register for the conference here. One-on-one meetings are available to registered investors via the conference website or by contacting their...

/ NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) — Red Pine Exploration Inc. (TSXV: RPX, OTCQB: RDEXF) (“Red Pine” or the “Company”) is pleased to announce that it has entered into an amendment agreement with Haywood Securities Inc. (“Haywood”), as co-lead underwriter and sole bookrunner, on its own behalf and on behalf of Research Capital Corporation, as co-lead underwriter (together with Haywood, the “Underwriters”), pursuant to which the Underwriters have agreed to purchase, on a “bought deal” private placement basis, (i) 22,223,000 common shares (the “Non-FT Shares”) of the Company at a price of C$0.090 per Non-FT Share (the “Non-FT Issue Price”), and (ii) any combination of (A) tranche 1 flow-through shares...